Skip to content
Menu

Cognition Therapeutics, Inc. CGTX

Full chart Compare
Set alert

Price alert · CGTX

All alert types
0.64 USD -0.04 (-6.03%)

Regular-session close

0.64 0.00 -0.28%

After hours · Nov 16, 7:18 PM ET

0.6052 Day range 0.69
0.595 52-week range 1.80
YTD
-52.68%
1 year
-58.79%
Market cap
60.75M
EPS (ttm)
-0.15
Shares out
41.55M
Forward P/E
-0.80
YTD return
-52.68%
1-year return
-58.79%
50-day average
0.47888
200-day average
1.23
Enterprise value
-7.19M
Volume
502.88K
Avg volume
464.03K
Open
0.69
Previous close
0.6798
Day's range
0.6052 – 0.69
52-week range
0.595 – 1.80
Beta
1.33
Analysts
Strong Buy
Price target
6.50 (+917.5%)

5D -0.0337 (-4.91%)

0.65000.67500.70000.7250MonTueWedThuFri0.6532

Key statistics

Price / book
0.81
Free cash flow
-29.72M
Total cash
28.53M
Total debt
809.00K
Return on equity
-108.31%
Short % of float
2.94%

Fundamental scorecard

5 of 25 checks passed on CGTX’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
CGTX Revenue — quarterly 0
CGTX Net income — quarterly -4.14M
CGTX EPS — quarterly -0.04

Earnings

CGTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 2024-0.24-0.25-0.01-4.17%
Aug 8, 2024Jun 1, 2024-0.22———
Aug 8, 2024Jun 1, 2024-0.22-0.18+0.04+18.18%
May 7, 2024Mar 1, 2024-0.23-0.27-0.04-17.39%
May 7, 2024Mar 1, 2024-0.23———
Mar 26, 2024Dec 1, 2023-0.38———

Upgrades / downgrades

CGTX analyst upgrades and downgrades
DateFirmActionFromTo
Dec 19, 2024B. Riley SecuritiesupNeutralBuy
Dec 19, 2024Chardan CapitalmainBuyBuy
Dec 19, 2024HC Wainwright & Co.mainBuyBuy
Nov 27, 2024HC Wainwright & Co.reitBuyBuy
Nov 15, 2024Chardan CapitalmainBuyBuy
Nov 4, 2024HC Wainwright & Co.reitBuyBuy

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
cogrx.com

News

Your note

Sign in to keep a note on CGTX — it syncs with the Stock Master app.

Insider holders

CGTX insider holders
InsiderRelationLatest transactionDateShares held
CAGGIANO ANTHONYOfficerStock Award(Grant)Feb 14, 2024141,629
DOYLE JOHN BRENDANChief Financial OfficerStock Award(Grant)Feb 14, 2024129,824
FLETCHER AARON G.L.Director and Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Jun 6, 20240
KHATTAR JACK ADirectorStock Award(Grant)Jun 6, 202414,500
KREIS LESLIE W JRDirector and Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Nov 7, 20230
MONIA BRETT PDirectorStock Award(Grant)Jun 6, 202414,500

Institution ownership

CGTX institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc2.99%1,242,554762.93KSep 29, 2024
Alyeska Investment Group, L.p.1.20%500,000307.00KSep 29, 2024
Geode Capital Management, LLC0.78%323,643198.72KSep 29, 2024
CM Management, LLC0.60%250,000153.50KSep 29, 2024
American Financial Group Inc.0.49%205,000125.87KSep 29, 2024
UBS Group AG0.48%197,859121.48KSep 29, 2024

Fund ownership

CGTX fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.43%1,009,905620.08KSep 29, 2024
Vanguard Extended Market Index Fund0.48%200,577123.15KSep 29, 2024
Fidelity Extended Market Index Fund0.46%192,260118.05KOct 30, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.18%76,70047.09KSep 29, 2024
iShares Micro Cap ETF0.17%71,61043.97KOct 30, 2024
Fidelity Total Market Index Fund0.14%59,26836.39KOct 30, 2024